Wu Kana, Zhai Mike Z, Weltzien Erin K, Cespedes Feliciano Elizabeth M, Meyerhardt Jeffrey A, Giovannucci Edward, Caan Bette J
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Cancer Causes Control. 2019 Feb;30(2):165-168. doi: 10.1007/s10552-018-1095-z. Epub 2018 Nov 15.
Liver diseases including non-alcoholic fatty liver disease (NAFLD) and ensuing alterations to the micro-environment may affect development of liver metastasis. Mirroring the rise in obesity rates, prevalence of NAFLD is increasing globally. Our objective was to examine the association between NAFLD and mortality in colorectal cancer patients.
Colorectal Cancer-Sarcopenia and Near-term Survival (C-SCANS) is a retrospective cohort study which included 3,262 stage I-III patients, aged 18-80 years, and diagnosed between 2006 and 2011 at Kaiser Permanente Northern California. Cox proportional hazards regression was used to calculate multivariable adjusted hazard ratios (HR) and 95% confidence intervals (CI).
After up to 10 years of follow-up, 879 deaths, including 451 from CRC were identified. Cases diagnosed with NAFLD before and within 1 month after CRC diagnosis (pre-existing NAFLD; n = 83) had a HR of 1.64 (95% CI 1.06-2.54) for overall and a HR of 1.85 (95% CI 1.03-3.30) for CRC-specific mortality compared to those without NAFLD. Findings did not differ significantly by sex, stage, tumor location, and smoking status, and were also similar when restricted to obese patients only.
Independent of body mass index and prognostic indicators, CRC patients with pre-existing NAFLD had a worse prognosis than those without NAFLD.
包括非酒精性脂肪性肝病(NAFLD)在内的肝脏疾病以及随之而来的微环境改变可能会影响肝转移的发生。随着肥胖率的上升,NAFLD在全球的患病率也在增加。我们的目的是研究NAFLD与结直肠癌患者死亡率之间的关联。
结直肠癌-肌肉减少症与近期生存率(C-SCANS)是一项回顾性队列研究,纳入了3262例年龄在18至80岁之间、于2006年至2011年在北加利福尼亚州凯撒医疗集团确诊为I-III期的患者。采用Cox比例风险回归分析来计算多变量调整后的风险比(HR)和95%置信区间(CI)。
经过长达10年的随访,共确定了879例死亡病例,其中包括451例死于结直肠癌。与无NAFLD的患者相比,在结直肠癌诊断前及诊断后1个月内被诊断为NAFLD的患者(即既往存在NAFLD;n = 83)的全因死亡HR为1.64(95% CI 1.06 - 2.54),结直肠癌特异性死亡HR为1.85(95% CI 1.03 - 3.30)。研究结果在性别、分期、肿瘤位置和吸烟状况方面无显著差异,仅纳入肥胖患者时结果也相似。
独立于体重指数和预后指标,既往存在NAFLD的结直肠癌患者的预后比无NAFLD的患者更差。